This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Psychiatric Times To Expand Coverage Of Mental Illness In Three Key Areas





NORWALK, Conn., Feb. 12, 2013 /PRNewswire/ -- UBM Medica US announces that Psychiatric Times -- the nation's best read psychiatric publication -- is pleased to announce that it will be expanding its coverage of mental disease in three key areas, with guidance from experts in bipolar disorder, neuropsychiatry, and sleep disorders. These experts will join members of the Editorial Board of Psychiatric Times to help keep psychiatrists up-to-date on the state-of-the-art of diagnosis and management of mental illness.

  • As Bipolar Disorder Section Editor, James Phelps, MD, will focus on practical solutions to problems that commonly arise in bipolar disease. Dr Phelps is Director of the Mood Disorders Program at Samaritan Mental Health in Corvallis, Oregon. He is the author of Why Am I Still Depressed? Recognizing and Managing the Ups and Downs of Bipolar II and Soft Bipolar Disorder.
  • As Neuropsychiatry Section Editor , Rakesh Jain, MD, MPH, will shed new light on the neurologic and psychiatric underpinnings of such mental disorders as schizophrenia, depression, and eating disorders. Dr Jain is Associate Clinical Professor of Psychiatry and Behavioral Sciences, University of Texas, Houston, and Director of Psychiatric Drug Research for the R/D Clinical Research Center at Lake Jackson, Texas
  • As Sleep Disorders Section Editor, Karl Doghramji, MD will explore the connection between psychiatric and sleep disorders. Dr Doghramji is Professor of Psychiatry, Neurology, and Medicine at Jefferson Medical College of Thomas Jefferson University, and Medical Director of the Jefferson Sleep Disorders Center at Thomas Jefferson University Hospital, in Philadelphia. Dr Doghramji is also Chair of the Albert M. Biele, MD Memorial Lectureship in Psychiatry in the Department of Psychiatry and Human Behavior at Jefferson Medical College.

About UBM Medica USAddressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach—online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, MusculoskeletalNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit http://www.UBMMedicaUS.com

Media contact:

Jason J. GoldenContent Marketing Manager203-523-7040 jason.golden@ubm.com

SOURCE UBM Medica US

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs